For qualified non-clinical research buyers, including independent researchers, educators, analysts and research teams. Not for human or veterinary use.

Research evidence guide

CJC-1295: the common name is not enough.

A cited guide to DAC and non-DAC identity, evidence tiers, analytical characterization and the questions research buyers should resolve before comparing listings.

Evidence snapshotPublished and regulatory sources distinguish structurally different materials associated with the CJC-1295 name. Exact identity must be documented.[1][5]

Compare current prices and formats.

For qualified non-clinical research buyers. Not for human or veterinary use.

Disclosure: We may earn a commission from purchases made through our links.

One common name, multiple research identities

A foundational paper identifies CJC-1295 as a modified hGRF(1-29) analog designed for albumin conjugation.[1] The FDA’s 2024 advisory review separately considered DAC and non-DAC forms and multiple counterions, emphasizing that the common name alone may not identify the intended compound.[5]

DAC-related evidencePreclinical and short healthy-volunteer biomarker studies concern specifically characterized albumin-binding material.[1][2]
Non-DAC gapResults involving DAC-related material cannot be assigned automatically to non-DAC products, unspecified salts or seller lots.[1][5]

What the published studies measured

A pair of short randomized studies in healthy adults reported sustained changes in circulating GH and IGF-I biomarkers after exposure to the studied long-acting analog.[2] Biomarker changes are not therapeutic outcomes, and the trials do not establish long-term safety or the suitability of commercial research material.

A separate study of 12 healthy men examined pulsatile secretion during exposure to an albumin-binding analog.[3] Its small sample and biomarker endpoint limit interpretation.

Identity boundary: DAC status, terminal modification, salt or counterion, sequence and molecular mass are material facts—not interchangeable naming details.

Analytical characterization matters

A forensic study used LC-HRMS/MS to identify a 29-amino-acid peptide in one unknown preparation and found the inferred sequence consistent with material marketed under the CJC-1295 name.[4] The study illustrates why analytical evidence is needed; it does not establish the identity or quality of other products.

FDA nomenclature and safety context

In a 2024 section 503A advisory proceeding, the FDA discussed inconsistent naming, missing characterization information and unknown long-term human safety across several CJC-1295-related bulk substances.[5] That proceeding concerns human-drug compounding and is not product-specific verification of a research-use seller lot.

Procurement essentials

  • Confirm DAC versus non-DAC identity and the exact terminal modification.
  • Request sequence, molecular formula, molecular mass and salt or counterion information.
  • Review lot-matched identity, assay, impurity and aggregation documentation when available.
  • Confirm storage requirements, lot traceability, shipping eligibility and returns.
  • Keep literature facts separate from seller-product and lot-specific records.

Compare current CJC-1295 research formats

The listings below are for qualified non-clinical research procurement. PRX does not infer chemical equivalence, purity, safety or expected results from the product name.

Sources

  1. Identification of CJC-1295 as a long-lasting GRF analog
  2. Prolonged stimulation of GH and IGF-I secretion by CJC-1295 in healthy adults
  3. Pulsatile secretion of growth hormone persists during continuous stimulation by CJC-1295
  4. Identification of CJC-1295 in an unknown pharmaceutical preparation
  5. FDA Pharmacy Compounding Advisory Committee transcript, December 4, 2024